Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation-Reference-Cited by-同舟云学术

Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

Published:2010-11 Issue:16 Volume:46 Page:3016-3021
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

de Jonge Maja J.A.,Slingerland Marije,Loos Walter J.,Wiemer Erik A.C.,Burger Herman,Mathijssen Ron H.J.,Kroep Judith R.,den Hollander Margret A.G.,van der Biessen Diane,Lam Mei-Ho,Verweij Jaap,Gelderblom Hans

Funder

LiPlasome Pharma A/S

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients;de Jongh;Br J Cancer,2003

2. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin;Go;J Clin Oncol,1999

3. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours;Planting;Br J Cancer,1993

4. Concept and clinical evaluation of carrier-mediated anticancer agents;Zamboni;Oncologist,2008

5. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer;White;Br J Cancer,2006

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemoradiotherapy and nanomedicine: Drug mechanisms and delivery systems;WIREs Nanomedicine and Nanobiotechnology;2024-07

2. Enzyme-responsive liposomes for controlled drug release;Drug Discovery Today;2024-07

3. Nanocarriers address intracellular barriers for efficient drug delivery, overcoming drug resistance, subcellular targeting and controlled release;Advanced Drug Delivery Reviews;2024-04

4. Platinum-based chemotherapy: trends in organic nanodelivery systems;Nanoscale;2024

5. Controlling the biodistribution and clearance of nanomedicines;Nature Reviews Bioengineering;2023-12-20